[
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "TM-Trabecular meshwork; SC-Schlemm’s canal and S-Sclera.Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).Effect of SB77 on Activation of RhoA and p_MLC Phosphorylation\nIn order to elucidate the effect of SB77 on RhoA/ROCK signal transduction, the pull-down assay for the active form of RhoA (GTP-RhoA) was carried out in HTM cell lysates after treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A representative IOP profile after SB77 treatment is shown in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, the SB77 (50 µM) treated eyes showed an overall increase in tracer quantity and area along the inner wall of SC after 24 h treatment as compared to vehicle treated eyes (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Effect of SB77 on Cell Viability\nTreatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Treatment with SB77 showed no significant effect on TM cell viability at all studied concentrations (Fig. 3A) (MTT assay).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In TUNEL assay, both SB77 and Y27632 (50 µM) treated cells showed no evidence of apoptosis (TUNEL-positive cells) as compared to DNase I treated cells (positive control) (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001, paired Student’s t-test.Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Immunofluorescence analysis revealed reduced actin bundles (F-actin), reduced vinculin-containing focal adhesions and reduced vimentin-containing intermediate filaments in drug treated cells as compared to vehicle controls (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Fig. 3. (C) Densitometry analysis of the results of 4B.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Immunoblot analysis revealed that HTM cells after treatment with either 50 µM SB77 or Y27632 showed significant reduction in the expression of vinculin, fibronectin, collagen 1 A (ECM protein) and vimentin as compared to vehicle controls (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Densitometry analysis showed a significant reduction in fold change in SB77-treated cells compared to Y27632 treated cells (p = 0.018 (vinculin); p = 0.000 (Fibronectin); p = 0.032 (COL1A) and p = 0.076 (vimentin)) (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Rho kinase inhibitor treatment significantly reduced the levels of GTP bound RhoA, thus inhibiting the activation of RhoA (p = 0.016 (vehicle control vs SB77-treated cells); p = 0.029 (vehicle control vs Y27632-treated cells)) (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Fig. 4. (B) Densitometry of Western blots of active RhoA normalized to total RhoA.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Y27632 treatment also showed similar fold changes, except for the larger change in COL4A1. β-catenin mRNA levels were reduced significantly in SB77- treated cells as compared to vehicle controls (p = 0.000) but it was not found to be significant when compared with Y27632-treated cells (p = 0.088), whereas COL4A1 was significantly reduced in Y27632 treated cells as compared to vehicle-treated cells (p = 0.001) (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "These dose levels were chosen based on the reported IC50 value12 and also based on the toxicity profile studied in HTM cells by MTT and TUNEL assays (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cytotoxicity assays indicate that SB77 at concentrations between 0.1–100 µM was not toxic to HTM cells (more than 95% viability; Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The maximum response to 50 µM SB77 treatment had not reached a plateau at 24 h (Fig. 2), perhaps because the drug response is greatly influenced by the freshness of the tissue27.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The increase in OF following SB77 was associated with increased tracer distribution (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Fig. 1), and reduction in actin stress fibers, cytoskeletal proteins and ECM proteins (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Our study revealed that the constitutive expression of Rho GTPase (active RhoA) was significantly reduced by both Y27632 (p = 0.029) and SB77 (p = 0.016) to essentially the same extent at the studied concentrations (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In the present study, a markedly greater reduction in p-MLC was observed in HTM cells treated with SB77 as compared to Y27632 treated cells (Fig. 6C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A highly significant reduction of β-catenin expression was achieved with SB77 treatment as compared to control (p = 0.000); however, it was not found to be statistically significant when compared with Y27632 (Fig. 6; p = 0.088).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The SB77-mediated OF increase is accompanied by the inactivation of RhoA and decreased p-MLC in cultured TM cells, and thus the action of SB77 is mediated at least in part through the ROCK/MLC II pathway (Fig. 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Fig. 1).Cytotoxicity Assay\nThe effect of SB77 on cell viability of HTM was measured by MTT based assay as per the manufacturer’s protocol.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  }
]